Navigation Links
GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™
Date:10/25/2010

ORLANDO, Fla., Oct. 25 /PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  Rankings are based on percentage of fiscal year growth during the period from 2005-2009.  GeneLink grew 2057 percent during this period. GeneLink ranked 17th overall in the Biotechnology/Pharmaceutical sector.

GeneLink's CEO Gary Beeman credits the Company's genetic science and its DNA-guided personalized health products for the dramatic revenue growth.  "GeneLink's growth is a testament to the pioneering research by our scientists over the past decade as well as an indicator of the growing interest in personalized wellness products customized to each individual's DNA."

"GeneLink and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader.  "Deloitte commends GeneLink for this impressive accomplishment."

"GeneLink has proven itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500," said Mark Jensen, managing partner, Venture Capital Services, Deloitte & Touch LLP.

GeneLink previously ranked 92nd in the  Deloitte "Fast 500" in 2008.


About GeneLink:

GeneLink is a wellness company engaged in genetic test and product development.  GeneLink's patented technologies include proprietary genetic assessments and products for personalized health, beauty and wellness.  For information, visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

As used in this document, "Deloitte" means Deloitte LLP.  Please see www.deloitte.com/us/about  for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.



'/>"/>
SOURCE GeneLink BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Announces HelixLife Private Label Distribution Agreement
2. GeneLink Reports First Quarter Gains
3. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
4. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
5. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
8. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
11. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Vermillion, Inc. (NASDAQ: VRML ... today announced the formation of the Steering Committee for ... --> Pelvic masses can present physicians ... management. Once pregnancy is ruled out, pelvic masses may ... advanced endometriosis, benign ovarian tumors and gastrointestinal and urinary ...
(Date:2/11/2016)... 2016  Wellcentive today announced it has been ... -based community care organization (CCO) with more ... quality reporting and care management solutions and services. ... of quality managers, analysts and care managers while ... serving FamilyCare members. Oregon ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
Breaking Biology Technology:
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/15/2016)... 15, 2016 Recent publicized breaches in cyber ... new ways to ensure data security and user authentication ... and Android that ties a user,s mobile ... into a hardware authorization token. Customer service agents who ... on their KodeKey enabled device to verify their identity. ...
Breaking Biology News(10 mins):